Published in J Clin Endocrinol Metab on June 01, 2003
11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med (2005) 2.12
Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing's disease: a 10-year experience. Ann Surg (2007) 1.81
Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum (2008) 1.73
Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart (2004) 1.69
Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab (2015) 1.47
The Treatment of Cushing's Disease. Endocr Rev (2015) 1.35
Cardiovascular consequences of cortisol excess. Vasc Health Risk Manag (2005) 1.32
Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. Br J Pharmacol (2009) 1.18
Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations. Pituitary (2014) 1.16
A measure of glucocorticoid load provided by DNA methylation of Fkbp5 in mice. Psychopharmacology (Berl) (2011) 1.16
Blood pressure in pediatric patients with Cushing syndrome. J Clin Endocrinol Metab (2009) 1.16
Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism. Endocrinol Metab Clin North Am (2014) 1.07
Neuropsychiatric disorders in Cushing's syndrome. Front Neurosci (2015) 1.06
Cushing's syndrome: epidemiology and developments in disease management. Clin Epidemiol (2015) 1.02
Quality of life in children and adolescents 1-year after cure of Cushing syndrome: a prospective study. Clin Endocrinol (Oxf) (2008) 0.99
Relative growth hormone deficiency and cortisol excess are associated with increased cardiovascular risk markers in obese adolescent girls. J Clin Endocrinol Metab (2009) 0.96
Quality of life and other outcomes in children treated for Cushing syndrome. J Clin Endocrinol Metab (2013) 0.95
The postoperative basal cortisol and CRH tests for prediction of long-term remission from Cushing's disease after transsphenoidal surgery. J Clin Endocrinol Metab (2011) 0.94
Resistant hypertension workup and approach to treatment. Int J Hypertens (2010) 0.94
Cushing's syndrome: all variants, detection, and treatment. Endocrinol Metab Clin North Am (2011) 0.90
Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI. J Clin Endocrinol Metab (2012) 0.89
Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery. World J Surg (2006) 0.89
The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. J Hypertens (2015) 0.88
11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis. FASEB J (2013) 0.88
Modulation of 11β-hydroxysteroid dehydrogenase as a strategy to reduce vascular inflammation. Curr Atheroscler Rep (2013) 0.83
Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study. Pituitary (2014) 0.81
Cardiac structure and function in Cushing's syndrome: a cardiac magnetic resonance imaging study. J Clin Endocrinol Metab (2014) 0.81
Comorbidities in Cushing's disease. Pituitary (2015) 0.79
Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension. BMC Endocr Disord (2015) 0.79
Association of abnormal lipid spectrum with the disease activity of Takayasu arteritis. Clin Rheumatol (2014) 0.78
Adamantyl ethanone pyridyl derivatives: potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1. ChemMedChem (2011) 0.78
Predictive value of retroperitoneal fat area measurement for detecting metabolic syndrome in patients undergoing adrenalectomy. World J Surg (2011) 0.78
Modulatory effect of BclI GR gene polymorphisms on the obesity phenotype in Brazilian patients with Cushing's disease. Clinics (Sao Paulo) (2013) 0.78
Discovery of adamantyl heterocyclic ketones as potent 11β-hydroxysteroid dehydrogenase type 1 inhibitors. ChemMedChem (2011) 0.77
Glucocorticoid excess induces long-lasting changes in body composition in male C57Bl/6J mice only with high-fat diet. Physiol Rep (2013) 0.77
The effect of alpha-lipoic acid on mitochondrial superoxide and glucocorticoid-induced hypertension. Oxid Med Cell Longev (2013) 0.77
A prospective study of appetite and food craving in 30 patients with Cushing's disease. Pituitary (2016) 0.76
Both transient and continuous corticosterone excess inhibit atherosclerotic plaque formation in APOE*3-leiden.CETP mice. PLoS One (2013) 0.76
Evaluation of Midnight Salivary Cortisol as a Predictor Factor for Common Carotid Arteries Intima Media Thickness in Patients with Clinically Inapparent Adrenal Adenomas. Int J Endocrinol (2015) 0.75
The risks of overlooking the diagnosis of secreting pituitary adenomas. Orphanet J Rare Dis (2016) 0.75
Vascular Dysfunction in Horses with Endocrinopathic Laminitis. PLoS One (2016) 0.75
Heart, lipids and hormones. Endocr Connect (2017) 0.75
Cushing's Disease: Subclinical Left Ventricular Systolic and Diastolic Dysfunction Revealed by Speckle Tracking Echocardiography and Tissue Doppler Imaging. Front Endocrinol (Lausanne) (2017) 0.75
Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med (2007) 6.58
Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev (2004) 3.14
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) (2006) 2.56
Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med (2002) 2.31
Advances in the treatment of prolactinomas. Endocr Rev (2006) 2.31
LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab (2013) 2.30
Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care (2012) 2.21
Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab (2002) 2.15
Endocrine disorders during the first year after autologous stem-cell transplant. Am J Med (2005) 2.14
Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med (2003) 2.09
The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab (2004) 2.01
Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol (2003) 1.79
The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states. Clin Endocrinol (Oxf) (2007) 1.73
Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res (2004) 1.67
BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporos Int (2005) 1.61
The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol (2005) 1.59
Traffic pollutants affect fertility in men. Hum Reprod (2003) 1.56
Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas. J Clin Endocrinol Metab (2009) 1.53
Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab (2004) 1.53
Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab (2007) 1.53
Effects of estrogen-progestin therapy on serum levels of RANKL, osteoprotegerin, osteocalcin, leptin, and ghrelin in postmenopausal women. Menopause (2007) 1.47
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab (2005) 1.44
The arginine growth hormone stimulation test in bradykinetic-rigid parkinsonisms. Mov Disord (2008) 1.43
The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab (2008) 1.41
Radioiodide induces apoptosis in human thyroid tissue in culture. Endocrine (2013) 1.39
Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World J Gastroenterol (2010) 1.35
Cushing's Syndrome. Endocrinol Metab Clin North Am (2008) 1.33
Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study. J Clin Endocrinol Metab (2005) 1.32
Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab (2004) 1.31
Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. Clin Endocrinol (Oxf) (2004) 1.29
Pathophysiology of diabetes mellitus in Cushing's syndrome. Neuroendocrinology (2010) 1.28
Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol (2007) 1.25
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin Endocrinol (Oxf) (2013) 1.22
Resistance to somatostatin analogs in acromegaly. Endocr Rev (2010) 1.20
Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab (2006) 1.20
Acromegaly and the cardiovascular system. Neuroendocrinology (2006) 1.16
Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation. Thyroid (2009) 1.16
HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res (2009) 1.16
Prolactin and autoimmunity. Pituitary (2005) 1.15
Vitamin D and cancer. Front Endocrinol (Lausanne) (2012) 1.15
Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer (2008) 1.13
Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab (2008) 1.13
Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab (2005) 1.13
The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am (2005) 1.12
Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab (2004) 1.12
Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review. Cancer (2003) 1.11
Are hepatic steatosis and carotid intima media thickness associated in obese patients with normal or slightly elevated gamma-glutamyl-transferase? J Transl Med (2012) 1.10
Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol (2002) 1.09
Differences of myocardial systolic deformation and correlates of diastolic function in competitive rowers and young hypertensives: a speckle-tracking echocardiography study. J Am Soc Echocardiogr (2010) 1.09
Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab (2004) 1.08
High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer (2002) 1.08
The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab (2004) 1.07
Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. Diabetes Care (2009) 1.07
Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol (2009) 1.07
Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab (2006) 1.06
Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. Clin Endocrinol (Oxf) (2003) 1.06